Treatment of children from 6 to 11 years old affected by moderate-severe atopic dermatitis with dupilumab: a first perspective from a single-center real-life experience in Italy

J Eur Acad Dermatol Venereol. 2022 Jun;36(6):e478-e480. doi: 10.1111/jdv.17963. Epub 2022 Feb 3.

Authors

C Colonna¹, M Zussino¹, N A Monzani^{2

3}, A Ponziani¹, R Cavalli¹

Affiliations

¹ Paediatric Dermatology Unit, Department of Clinical Sciences and Community Health, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
² Neonatal Intensive Care Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
³ Department of Clinical Sciences and Community Health, Università degli Studi di Milano, Milan, Italy.

PMID: 35067995
DOI: 10.1111/jdv.17963

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use
Child
Dermatitis, Atopic* / drug therapy
Humans
Italy
Severity of Illness Index
Treatment Outcome

Substances

Antibodies, Monoclonal, Humanized
dupilumab